W‘ALK’ Into the Next Stage

Gouji Toyokawa, Takashi Seto, Mitsuhiro Takenoyama, Yukito Ichinose

研究成果: ジャーナルへの寄稿評論記事

4 引用 (Scopus)

抜粋

In 2007, the rearrangement of anaplastic lymphoma kinase (ALK) was identified to be associated with the pathogenesis of a subset of patients with non–small-cell lung cancer (NSCLC). Surprisingly, approximately 4 years after the discovery of ALK rearrangement in lung cancer, the first-in-class ALK inhibitor (ALKi), crizotinib, was approved for metastatic ALK-rearranged NSCLC by the US Food and Drug Administration. Subsequently, next-generation ALKis, such as alectinib and ceritinib, have been developed, and some of them have been applied in the clinical setting. Furthermore, various resistance mechanisms against ALKis have been gradually elucidated, and treatment strategies according to such resistance have been proposed. In addition, novel ALKis exhibit good antitumor efficacy for brain metastases. Thus, we now know much about ALK-rearranged NSCLC; however, is it enough? Several concerns, such as the optimal sequence of ALKis, significance of antiangiogenic therapy, immune checkpoint therapy, and cytotoxic chemotherapy in ALK-rearranged NSCLC, should be clearly addressed, which would lead to the establishment of optimal treatment strategies and a more prolonged survival in patients with ALK rearrangement. Thus, we should w‘ALK’ into the next stage.

元の言語英語
ページ(範囲)122-126
ページ数5
ジャーナルClinical Lung Cancer
18
発行部数2
DOI
出版物ステータス出版済み - 3 1 2017

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

フィンガープリント W‘ALK’ Into the Next Stage' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用

    Toyokawa, G., Seto, T., Takenoyama, M., & Ichinose, Y. (2017). W‘ALK’ Into the Next Stage. Clinical Lung Cancer, 18(2), 122-126. https://doi.org/10.1016/j.cllc.2016.10.005